Clinical Trials Logo

Oligosymptomatic PSP (oPSP) clinical trials

View clinical trials related to Oligosymptomatic PSP (oPSP).

Filter by:
  • None
  • Page 1

NCT ID: NCT04363684 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Start date: March 1, 2020
Phase:
Study type: Observational

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

NCT ID: NCT02365922 Completed - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

ARTFL
Start date: September 2014
Phase:
Study type: Observational

Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at 14 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes.